CTLA-4/PD-1/PD-L1定向的免疫检查点抑制剂（ICIs）是晚期非小细胞肺癌（NSCLC）治疗的标准疗法之一。然而，一些新型单克隆抗体正在成为NSCLC的有前途的治疗方法。因此，本文旨在全面评价最近获批的和新兴单克隆抗体免疫检查点抑制剂对晚期NSCLC的治疗作用。未来需要进行更广泛的研究，以探讨新的ICIs的有望数据。未来的III期试验可以充分评估每个免疫检查点在肿瘤微环境更广泛环境中的作用，从而选择最佳的新型ICIs，最佳方法以及最有效的受试者子集。

CTLA-4/PD-1/PD-L1- directed immune checkpoint inhibitors (ICIs) are one of the standard therapies for the treatment of advanced non-small cell lung cancer (NSCLC). However, some new classes of monoclonal antibodies are emerging as promising therapies for advanced NSCLC.Therefore, this paper aims to provide a comprehensive review of the recently approved as well as emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced NSCLC.Further and larger studies will be needed to explore the promising emerging data on new ICIs. Future phase III trials could allow us to properly assess the role of each immune checkpoints in the wider context of the tumor microenvironment and thus the best new ICIs to use, the best approach and the most effective subset of patients to select.